Your browser doesn't support javascript.
loading
A pleiotropic variant in DNAJB4 is associated with multiple myeloma risk.
Dicanio, Marco; Giaccherini, Matteo; Clay-Gilmour, Alyssa; Macauda, Angelica; Sainz, Juan; Machiela, Mitchell J; Rybicka-Ramos, Malwina; Norman, Aaron D; Tyczynska, Agata; Chanock, Stephen J; Barington, Torben; Kumar, Shaji K; Bhatti, Parveen; Cozen, Wendy; Brown, Elizabeth E; Suska, Anna; Haastrup, Eva K; Orlowski, Robert Z; Dudzinski, Marek; Garcia-Sanz, Ramon; Kruszewski, Marcin; Martinez-Lopez, Joaquin; Beider, Katia; Iskierka-Jazdzewska, Elzbieta; Pelosini, Matteo; Berndt, Sonja I; Razny, Malgorzata; Jamroziak, Krzysztof; Rajkumar, S Vincent; Jurczyszyn, Artur; Vangsted, Annette Juul; Collado, Pilar Garrido; Vogel, Ulla; Hofmann, Jonathan N; Petrini, Mario; Butrym, Aleksandra; Slager, Susan L; Ziv, Elad; Subocz, Edyta; Giles, Graham G; Andersen, Niels Frost; Mazur, Grzegorz; Watek, Marzena; Lesueur, Fabienne; Hildebrandt, Michelle A T; Zawirska, Daria; Ebbesen, Lene Hyldahl; Marques, Herlander; Gemignani, Federica; Dumontet, Charles.
Afiliação
  • Dicanio M; Department of Biology, University of Pisa, Pisa, Italy.
  • Giaccherini M; Department of Biology, University of Pisa, Pisa, Italy.
  • Clay-Gilmour A; Department of Epidemiology and Biostatistics, Arnold School of Public Health, University of South Carolina, Greenville, South Carolina, USA.
  • Macauda A; Genomic Epidemiology Group, German Cancer Research Center (DKFZ), Heidelberg, Germany.
  • Sainz J; Genomic Oncology Area, GENYO. Center for Genomics and Oncological Research: Pfizer, University of Granada/Andalusian Regional Government, Granada, Spain.
  • Machiela MJ; Department of Hematology, Virgen de las Nieves University Hospital, Granada, Spain.
  • Rybicka-Ramos M; Department of Medicine, University of Granada, Granada, Spain.
  • Norman AD; Division of Cancer Epidemiology and Genetics, National Cancer Institute, National Institues of Health, Bethesda, Maryland, USA.
  • Tyczynska A; Department of Hematology Specialist Hospital No. 1, Bytom, Poland.
  • Chanock SJ; Division of Epidemiology, Department of Health Sciences Research, Mayo Clinic, Rochester, Ontario, USA.
  • Barington T; Division of Biomedical Statistics and Informatics, Department of Health Sciences Research, Mayo Clinic, Rochester, Ontario, USA.
  • Kumar SK; Department of Hematology and Transplantology, Medical University of Gdansk, Gdansk, Poland.
  • Bhatti P; Division of Cancer Epidemiology and Genetics, National Cancer Institute, National Institues of Health, Bethesda, Maryland, USA.
  • Cozen W; Department of Hematology, Rigshospitalet, Copenhagen, Denmark.
  • Brown EE; Division of Hematology, Department of Internal Medicine, Mayo Clinic, Rochester, Ontario, USA.
  • Suska A; Cancer Control Research, BC Cancer, Vancouver, Canada.
  • Haastrup EK; Program in Epidemiology, Public Health Sciences Division, Fred Hutchinson Cancer Research Center, Seattle, Washington, USA.
  • Orlowski RZ; Division of Hematology/Oncology, Department of Medicine, School of Medicine, Susan and Henry Samueli College of Health Sciences, Chao Family Comprehensive Cancer Center, University of California, Irvine, California, USA.
  • Dudzinski M; Department of Pathology, School of Medicine, Susan and Henry Samueli College of Health Sciences, Chao Family Comprehensive Cancer Center, University of California, Irvine, California, USA.
  • Garcia-Sanz R; Department of Pathology, School of Medicine, University of Alabama at Birmingham, Birmingham, Alabama, USA.
  • Kruszewski M; Plasma Cell Dyscrasia Center Department of Hematology Jagiellonian University Faculty of Medicine, Kraków, Poland.
  • Martinez-Lopez J; Department of Hematology, Rigshospitalet, Copenhagen, Denmark.
  • Beider K; Department of Lymphoma - Myeloma, Division of Cancer Medicine, University of Texas MD Anderson Cancer Center, Houston, Texas, USA.
  • Iskierka-Jazdzewska E; Department of Hematology, Institute of Medical Sciences, College of Medical Sciences, University of Rzeszow, Rzeszow, Poland.
  • Pelosini M; Medina A. Department of Hematology, University Hospital of Salamanca (HUS/IBSAL), CIBERONC and Cancer Research Institute of Salamanca-IBMCC (USAL-CSIC), Salamanca, Spain.
  • Berndt SI; Department of Hematology, University Hospital No. 2 in Bydgoszcz, Bydgoszcz, Poland.
  • Razny M; Hospital 12 de Octubre, Compluntense University, CNIO, CIBERONC, Madrid, Spain.
  • Jamroziak K; Hematology Division Chaim Sheba Medical Center, Tel Hashomer, Israel.
  • Rajkumar SV; Department of Hematology, Medical University of Lodz, Lódz, Poland.
  • Jurczyszyn A; U.O. Dipartimento di Ematologia, Azienda USL Toscana Nord Ovest, Livorno, Italy.
  • Vangsted AJ; Division of Cancer Epidemiology and Genetics, National Cancer Institute, National Institues of Health, Bethesda, Maryland, USA.
  • Collado PG; Department of Hematology, Rydygier Hospital, Cracow, Poland.
  • Vogel U; Department of Hematology, Institute of Hematology and Transfusion Medicine, Warsaw, Poland.
  • Hofmann JN; Division of Hematology, Department of Internal Medicine, Mayo Clinic, Rochester, Ontario, USA.
  • Petrini M; Plasma Cell Dyscrasia Center Department of Hematology Jagiellonian University Faculty of Medicine, Kraków, Poland.
  • Butrym A; Department of Hematology, Rigshospitalet, Copenhagen, Denmark.
  • Slager SL; Department of Hematology, Virgen de las Nieves University Hospital, Granada, Spain.
  • Ziv E; National Research Center for the Working Environment, Copenhagen, Denmark.
  • Subocz E; Division of Cancer Epidemiology and Genetics, National Cancer Institute, National Institues of Health, Bethesda, Maryland, USA.
  • Giles GG; Hematology Unit, Department of Clinical and Experimental Medicine, University of Pisa, Pisa, Italy.
  • Andersen NF; Department of Cancer Prevention and Therapy, Wroclaw Medical University, Wroclaw, Poland.
  • Mazur G; Division of Epidemiology, Department of Health Sciences Research, Mayo Clinic, Rochester, Ontario, USA.
  • Watek M; Department of Medicine, University of California San Francisco Helen Diller Family Comprehensive Cancer Center, San Francisco, California, USA.
  • Lesueur F; Department of Hematology, Military Institute of Medicine, Warsaw, Poland.
  • Hildebrandt MAT; Cancer Epidemiology Division, Cancer Council Victoria, Melbourne, Victoria, Australia.
  • Zawirska D; Center for Epidemiology and Biostatistics, School of Population and Global Health, The University of Melbourne, Melbourne, Victoria, Australia.
  • Ebbesen LH; Precision Medicine, School of Clinical Sciences at Monash Health, Monash University, Clayton, Victoria, Australia.
  • Marques H; Department of Hematology, Rigshospitalet, Copenhagen, Denmark.
  • Gemignani F; Department of Internal Diseases, Occupational Medicine, Hypertension and Clinical Oncology, Wroclaw Medical University, Wroclaw, Poland.
  • Dumontet C; Department of Hematology, Institute of Hematology and Transfusion Medicine, Warsaw, Poland.
Int J Cancer ; 152(2): 239-248, 2023 01 15.
Article em En | MEDLINE | ID: mdl-36082445
Assuntos
Palavras-chave
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Mieloma Múltiplo Tipo de estudo: Etiology_studies / Risk_factors_studies Limite: Humans Idioma: En Ano de publicação: 2023 Tipo de documento: Article
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Mieloma Múltiplo Tipo de estudo: Etiology_studies / Risk_factors_studies Limite: Humans Idioma: En Ano de publicação: 2023 Tipo de documento: Article